First-in-human fluorescence imaging-guided surgery and drug delivery in solid tumors

Guolan Lu

doi:10.1117/12.2595597

6 March 2021 First-in-human fluorescence imaging-guided surgery and drug delivery in solid tumors

Guolan Lu

Proceedings Volume 11625, Molecular-Guided Surgery: Molecules, Devices, and Applications VII; 116250Y (2021) https://doi.org/10.1117/12.2595597
Event: SPIE BiOS, 2021, Online Only

Abstract

Surgery and systemic therapy are the backbone treatment methods for solid tumors. However, incomplete surgical resection and poor response to systemic therapy have resulted in substantial cancer-related mortality and morbidity worldwide. Antibody-based fluorescence imaging holds great potential to enable precise surgical resection and improve our understanding of the mechanism driving resistance to systemic therapy in clinical tumors. In this talk, I will present our recent work on translating fluorescently labeled therapeutic antibodies for surgical navigation and for quantitating antibody delivery in solid tumors in first-in-human trials.

Conference Presentation

Citation Download Citation

Guolan Lu "First-in-human fluorescence imaging-guided surgery and drug delivery in solid tumors", Proc. SPIE 11625, Molecular-Guided Surgery: Molecules, Devices, and Applications VII, 116250Y (6 March 2021); https://doi.org/10.1117/12.2595597

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available